ARTICLE SUMMARY:
Among cancers, colorectal cancer is uniquely amenable to screening and prevention efforts, yet many who are eligible have not been screened. Efforts to change this paradigm have spawned a number of promising new technologies, but companies face an uphill battle when it comes to gaining widespread acceptance and payor coverage in the US.
Cancer management is leading the charge toward more personalized healthcare, thanks to our rapidly expanding knowledge of (and ability to map out) patient- and tumor-specific genetic mutations associated with various cancers, and the introduction of new biologic drugs that target those mutations.
